441 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag http://www.zacks.com/stock/news/359874/aveo-pharmaceuticals-aveo-q4-earnings-beat-revenues-lag?cid=CS-ZC-FT-359874 Mar 15, 2019 - AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Here's Why Momentum Investors Will Love Astrazeneca (AZN) http://www.zacks.com/stock/news/359525/heres-why-momentum-investors-will-love-astrazeneca-azn?cid=CS-ZC-FT-359525 Mar 14, 2019 - Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Britain Headed for a Soft Brexit? 5 Picks http://www.zacks.com/stock/news/359442/is-britain-headed-for-a-soft-brexit-5-picks?cid=CS-ZC-FT-359442 Mar 14, 2019 - Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Bayer Submits Application in EU for Prostate Cancer Drug http://www.zacks.com/stock/news/358754/bayer-submits-application-in-eu-for-prostate-cancer-drug?cid=CS-ZC-FT-358754 Mar 11, 2019 - Bayer (BAYRY) submits an MAA for darolutamide in EU for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps http://www.zacks.com/stock/news/358687/sanofis-dupixent-gets-fda-priority-status-for-nasal-polyps?cid=CS-ZC-FT-358687 Mar 11, 2019 - Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-ZC-FT-357836 Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 http://www.zacks.com/stock/news/357189/mallinckrodt-mnk-rallies-as-earnings-beat-estimates-in-q4?cid=CS-ZC-FT-357189 Feb 27, 2019 - Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/357173/bayer-bayry-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-357173 Feb 27, 2019 - Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.

Pages: 1234567891011...45

<<<Page 6>